Xact Kapitalforvaltning AB Increases Holdings in Amgen Inc. (AMGN)
Xact Kapitalforvaltning AB raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.4% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 124,819 shares of the medical research company’s stock after buying an additional 1,722 shares during the quarter. Xact Kapitalforvaltning AB’s holdings in Amgen were worth $21,498,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. American National Bank raised its stake in Amgen by 0.9% during the second quarter. American National Bank now owns 25,957 shares of the medical research company’s stock valued at $4,471,000 after buying an additional 231 shares in the last quarter. Pioneer Trust Bank N A OR raised its stake in Amgen by 1.6% during the second quarter. Pioneer Trust Bank N A OR now owns 18,675 shares of the medical research company’s stock valued at $3,217,000 after buying an additional 290 shares in the last quarter. First PREMIER Bank raised its stake in Amgen by 5.6% during the second quarter. First PREMIER Bank now owns 8,742 shares of the medical research company’s stock valued at $1,506,000 after buying an additional 460 shares in the last quarter. Copper Rock Capital Partners LLC raised its stake in Amgen by 70.9% during the second quarter. Copper Rock Capital Partners LLC now owns 3,301 shares of the medical research company’s stock valued at $483,000 after buying an additional 1,370 shares in the last quarter. Finally, Triangle Securities Wealth Management raised its stake in Amgen by 0.8% during the second quarter. Triangle Securities Wealth Management now owns 12,054 shares of the medical research company’s stock valued at $2,076,000 after buying an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 78.14% of the company’s stock.
Shares of Amgen Inc. (AMGN) traded down 1.04% during trading on Friday, reaching $187.47. The company’s stock had a trading volume of 5,348,992 shares. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $191.10. The company’s 50-day moving average is $175.31 and its 200-day moving average is $169.32. The company has a market capitalization of $136.79 billion, a P/E ratio of 17.08 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter in the previous year, the company posted $2.84 EPS. Amgen’s revenue was up 2.1% on a year-over-year basis. On average, analysts forecast that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were given a $1.15 dividend. This represents a $4.60 annualized dividend and a yield of 2.45%. The ex-dividend date was Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is presently 41.93%.
A number of analysts have recently weighed in on AMGN shares. Cann reiterated a “buy” rating on shares of Amgen in a research report on Monday, August 28th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $203.00 price target on shares of Amgen in a research report on Thursday, September 7th. Deutsche Bank AG started coverage on Amgen in a research report on Friday, June 23rd. They set a “hold” rating and a $172.00 price target on the stock. ValuEngine cut Amgen from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, William Blair reiterated a “market perform” rating on shares of Amgen in a research report on Monday, June 26th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $186.14.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.